Lv3
364 积分 2022-05-16 加入
LC-MF-4, a Novel FGFR3 Degrader for Therapeutic Intervention in FGFR3-Altered Cancers
4小时前
已完结
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use
1天前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
3天前
已完结
Discovery of LYA914, An Orally Bioavailable PROTAC Degrader Targeting the DNA Binding Domain of the Androgen Receptor for the Treatment of CRPC
3天前
已完结
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
3天前
已完结
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers
3天前
已完结
Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation
3天前
已完结
Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer
3天前
已完结
Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia
3天前
已完结
Discovery of a Series of 7‑Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement
3天前
已完结
皖公网安备34019202002308
